Cytori Therapeutics recently revealed three-year clinical follow-up data of the SCLERADEC I trial (NCT01813279), showing that the improvement…
Articles by Joana Fernandes, PhD
Corbus Pharmaceuticals’Â experimental therapy Resunab (JBT-101) shows promise in a clinical trial for the treatment of diffuse cutaneous systemic sclerosis…
Intravenous administration of iloprost may stabilize and improve symptoms of dysfunctional cardiopulmonary and blood vessel activity in patients with systemic…
Two approved treatments for pulmonary arterial hypertension — Tracleer (bosentan) and Opsumit (macitentan) — can block a molecular pathway that…
Patients with systemic sclerosis and Raynaud’s syndrome have a high risk of developing other organ complications within two years after the onset…
Exposure to low temperatures and emotional stress triggers the production of norepinephrine (adrenaline), which contributes to skin fibrosis in patients…
A new study showed that certain proteins present in the blood can serve as reliable biomarkers for the detection of…